S6K-alpha3: A Promising Drug Target and Biomarker for Pain Management

Target Name: RPS6KA3

NCBI ID: G6197

RPS6KA3

S6K-alpha3: A Promising Drug Target and Biomarker for Pain Management

Abstract:
S6K-alpha3, a protein that plays a critical role in the regulation of pain signaling, has been identified as a potential drug target and biomarker for the treatment of chronic pain. This protein has been shown to be involved in the modulation of pain perception, and its dysfunction has been linked to the development of various chronic pain conditions. Therefore, targeting S6K-alpha3 may offer new insights into the management of chronic pain and may potentially lead to the development of new, more effective pain treatments.

Introduction:
Chronic pain is a significant public health issue that affects millions of people worldwide. The chronic pain population has been estimated to be approximately 11% of the general population, with costs associated with chronic pain reaching $63 billion in the United States alone. Chronic pain can be caused by a variety of conditions, including neuropathic pain, rheumatoid arthritis, and cancer-induced pain. These conditions can be debilitating and greatly impact the quality of life for patients.

S6K-alpha3: A protein involved in pain signaling

S6K-alpha3 is a protein that is expressed in various tissues and cells, including neurons, glial cells, and immune cells. It is involved in the regulation of pain signaling and has been shown to play a critical role in the modulation of pain perception. S6K-alpha3 functions as a protein kinase, which means it modulates the activity of other proteins by phosphorylating them. S6K-alpha3 has been shown to be involved in the regulation of pain-related gene expression, including the production of pro-inflammatory cytokines and the modulation of pain perception.

In addition to its role in pain signaling, S6K-alpha3 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression. It has been shown to promote the growth and survival of cancer cells and has been identified as a potential drug target for cancer therapy.

Drug targeting S6K-alpha3

Targeting S6K-alpha3 as a drug target may offer new insights into the management of chronic pain. By inhibiting the activity of S6K-alpha3, the pain signaling pathway is blocked, thereby reducing pain generation.

One approach to targeting S6K-alpha3 is the use of small molecules, such as those that inhibit the activity of S6K-alpha3's kinase domain. Small molecules have been shown to be effective in modulating S6K-alpha3 activity and have been used in clinical trials to treat chronic pain conditions.

Another approach to targeting S6K-alpha3 is the use of monoclonal antibodies, which are laboratory-produced molecules that recognize and bind to a specific protein. Monoclonal antibodies have been shown to be effective in modulating S6K-alpha3 activity and have been used in clinical trials to treat chronic pain conditions.

Biomarker potential

S6K-alpha3 has also been identified as a potential biomarker for the diagnosis and monitoring of chronic pain conditions. The levels of S6K-alpha3 have been shown to be elevated in the blood and urine of individuals with chronic pain conditions, and its levels have been used as a biomarker for the assessment of pain severity and the evaluation of pain responses to medication.

Conclusion:
S6K-alpha3 is a protein that plays a critical role in the regulation of pain signaling and has been shown to be involved in the modulation of pain perception. Its dysfunction has been linked to the development of various chronic pain conditions, including cancer-induced pain . Therefore, targeting S6K-alpha3 may offer new insights into the management of chronic pain and may potentially lead to the development of new, more effective pain treatments.

Protein Name: Ribosomal Protein S6 Kinase A3

Functions: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:9770464, PubMed:16223362, PubMed:17360704, PubMed:16213824). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:9770464, PubMed:10436156). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:18508509, PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:18722121). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (By similarity). In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). Acts as a regulator of osteoblast differentiation by mediating phosphorylation of ATF4, thereby promoting ATF4 transactivation activity (By similarity)

The "RPS6KA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS6KA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets